Enteric Coated Prostaglandin Composition for Chloride Channel Openers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chloride channel openers used for treating constipation often cause adverse side effects such as nausea, and there is a need for a composition that can provide improved pharmaceutical effects while minimizing these adverse effects.
Innovation Solution
An enteric coated composition for oral administration containing a chloride channel opener, preferably a ClC-2 channel opener, such as a prostaglandin compound, is developed to reduce nausea and enhance pharmaceutical efficacy by using an enteric coating that protects the compound from acidic conditions, maintaining the bicyclic tautomer form and preventing ring opening in the gastric juice.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a chloride channel opener is administered orally without enteric coating, then the pharmaceutical effect is achieved, but nausea and adverse side effects occur
Solution Approach 1:
The enteric coating is applied in advance to the chloride channel opener before administration, creating a protective barrier that prevents direct contact with gastric juice. This preliminary protective action ensures the compound reaches the intestine intact, achieving the desired pharmaceutical effect while preventing nausea caused by gastric irritation.
Solution Approach 2:
The enteric coating acts as an intermediary substance between the chloride channel opener and the gastric environment. It mediates the interaction by providing a protective interface that allows the compound to survive gastric conditions and release its active ingredient only in the appropriate intestinal environment, thereby eliminating nausea while maintaining efficacy.
2Reliability
If the chloride channel opener is exposed to acidic gastric conditions, then ring opening occurs reducing efficacy, but the enteric coating prevents this degradation
Solution Approach 1:
The enteric coating is applied in advance to protect the bicyclic tautomer form from acidic degradation. This preliminary protective measure ensures the compound maintains its stable bicyclic structure during gastric transit, preventing ring opening and ensuring pharmaceutical efficacy is preserved until intestinal release.
Solution Approach 2:
The enteric coating serves as a protective intermediary that shields the chloride channel opener from direct exposure to gastric acid. This intermediary layer prevents the acid-catalyzed ring opening reaction, maintaining the stable bicyclic tautomer form throughout gastric transit and ensuring the compound remains pharmacologically active.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enteric coated composition effectively reduces nausea and enhances the enteric pooling effect, providing improved pharmaceutical benefits by maintaining the bicyclic tautomer form and preventing ring opening, thus enhancing the treatment of constipation and bowel cleansing.
Implementation Method 1
an enteric coating for oral administration containing a chloride channel opener, preferably a ClC-2 channel opener, such as a prostaglandin compound, is developed to reduce nausea and enhance pharmaceutical efficacy by using an enteric coating that protects the compound from acidic conditions
Implementation Method 2
maintaining the bicyclic tautomer form and preventing ring opening in the gastric juice
Data Source
AI summary
The present invention provides an enteric coated composition for oral administration of a chloride channel opener which can provide improved pharmaceutical activity with reduced adverse side effect such as nausea.